Human IgM monoclonal antibody 16.88: Pharmacokinetics and immunogenicity in colorectal cancer patients

Hidde J. Haisma, Herbert M. Pinedo, Mieke A P Kessel, Monique Van Muijen, Jan C. Roos, Marian A B D Plaizier, Harrie J M Martens, Robert DeJager, Epie Boven

Research output: Contribution to journalArticle

Abstract

Twenty colorectal cancer patients were given an intravenous injection of human IgM monoclonal antibody (MAb) 16.88 (8 mg) conjugated to 131I for tumor localization. After a 2-week interval, a second injection with 200, 500, or 1000 mg of unlabeled antibody added was given to groups of five patients each. At the end of the 2-hour infusion, 66% of the radioactivity remained in the circulation. Blood clearance of the 131I-labeled MAb 16.88 was biphasic with a mean half-life (T1/2α) of 12 hours and T1/2β of 45 hours. Clearance rate was 0.09 L/hour. More than 90% of the 131I in serum was protein bound, with an immunoreactive fraction of 80% in the first 48 hours. Size exclusion chromatography indicated no degradation products other than 131I in serum and urine. The urinary excretion rate of 131I increased to 1.5% of the dose per hour at 24 hours, with 50% of the dose excreted in 34 hours. The pharmacokinetic profile of 131I-labeled MAb 16.88 was neither influenced by the total protein dose of antibody administered nor affected by specific uptake in tumor tissue in individual patients, as determined on early immunoscintigrams. The larger antibody doses showed a slightly slower excretion of 131I. The assays applied to determine immunogenicity were enzyme-linked immunosorbent assay, radioimmunoassay, and the dot-blot assay. They had sensitivities ranging from 5 ng/mL to 0.5 μg/mL for goat or rabbit antihuman IgM. The assays did not reveal antihuman antibody responses.

Original languageEnglish (US)
Pages (from-to)1813-1819
Number of pages7
JournalJournal of the National Cancer Institute
Volume83
Issue number24
StatePublished - Dec 18 1991
Externally publishedYes

Fingerprint

Colorectal Cancer
Monoclonal antibodies
Pharmacokinetics
Monoclonal Antibody
Antibody
Antibodies
Immunoglobulin M
Colorectal Neoplasms
Assays
Dose
Monoclonal Antibodies
Clearance
Tumors
Tumor
Injection
Proteins
Protein
Enzyme-linked Immunosorbent Assay
Goats
Intravenous Injections

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Statistics, Probability and Uncertainty
  • Applied Mathematics
  • Physiology (medical)
  • Radiology Nuclear Medicine and imaging

Cite this

Haisma, H. J., Pinedo, H. M., Kessel, M. A. P., Van Muijen, M., Roos, J. C., Plaizier, M. A. B. D., ... Boven, E. (1991). Human IgM monoclonal antibody 16.88: Pharmacokinetics and immunogenicity in colorectal cancer patients. Journal of the National Cancer Institute, 83(24), 1813-1819.

Human IgM monoclonal antibody 16.88 : Pharmacokinetics and immunogenicity in colorectal cancer patients. / Haisma, Hidde J.; Pinedo, Herbert M.; Kessel, Mieke A P; Van Muijen, Monique; Roos, Jan C.; Plaizier, Marian A B D; Martens, Harrie J M; DeJager, Robert; Boven, Epie.

In: Journal of the National Cancer Institute, Vol. 83, No. 24, 18.12.1991, p. 1813-1819.

Research output: Contribution to journalArticle

Haisma, HJ, Pinedo, HM, Kessel, MAP, Van Muijen, M, Roos, JC, Plaizier, MABD, Martens, HJM, DeJager, R & Boven, E 1991, 'Human IgM monoclonal antibody 16.88: Pharmacokinetics and immunogenicity in colorectal cancer patients', Journal of the National Cancer Institute, vol. 83, no. 24, pp. 1813-1819.
Haisma HJ, Pinedo HM, Kessel MAP, Van Muijen M, Roos JC, Plaizier MABD et al. Human IgM monoclonal antibody 16.88: Pharmacokinetics and immunogenicity in colorectal cancer patients. Journal of the National Cancer Institute. 1991 Dec 18;83(24):1813-1819.
Haisma, Hidde J. ; Pinedo, Herbert M. ; Kessel, Mieke A P ; Van Muijen, Monique ; Roos, Jan C. ; Plaizier, Marian A B D ; Martens, Harrie J M ; DeJager, Robert ; Boven, Epie. / Human IgM monoclonal antibody 16.88 : Pharmacokinetics and immunogenicity in colorectal cancer patients. In: Journal of the National Cancer Institute. 1991 ; Vol. 83, No. 24. pp. 1813-1819.
@article{60131e0d556a4e979b1238f4a3466848,
title = "Human IgM monoclonal antibody 16.88: Pharmacokinetics and immunogenicity in colorectal cancer patients",
abstract = "Twenty colorectal cancer patients were given an intravenous injection of human IgM monoclonal antibody (MAb) 16.88 (8 mg) conjugated to 131I for tumor localization. After a 2-week interval, a second injection with 200, 500, or 1000 mg of unlabeled antibody added was given to groups of five patients each. At the end of the 2-hour infusion, 66{\%} of the radioactivity remained in the circulation. Blood clearance of the 131I-labeled MAb 16.88 was biphasic with a mean half-life (T1/2α) of 12 hours and T1/2β of 45 hours. Clearance rate was 0.09 L/hour. More than 90{\%} of the 131I in serum was protein bound, with an immunoreactive fraction of 80{\%} in the first 48 hours. Size exclusion chromatography indicated no degradation products other than 131I in serum and urine. The urinary excretion rate of 131I increased to 1.5{\%} of the dose per hour at 24 hours, with 50{\%} of the dose excreted in 34 hours. The pharmacokinetic profile of 131I-labeled MAb 16.88 was neither influenced by the total protein dose of antibody administered nor affected by specific uptake in tumor tissue in individual patients, as determined on early immunoscintigrams. The larger antibody doses showed a slightly slower excretion of 131I. The assays applied to determine immunogenicity were enzyme-linked immunosorbent assay, radioimmunoassay, and the dot-blot assay. They had sensitivities ranging from 5 ng/mL to 0.5 μg/mL for goat or rabbit antihuman IgM. The assays did not reveal antihuman antibody responses.",
author = "Haisma, {Hidde J.} and Pinedo, {Herbert M.} and Kessel, {Mieke A P} and {Van Muijen}, Monique and Roos, {Jan C.} and Plaizier, {Marian A B D} and Martens, {Harrie J M} and Robert DeJager and Epie Boven",
year = "1991",
month = "12",
day = "18",
language = "English (US)",
volume = "83",
pages = "1813--1819",
journal = "Journal of the National Cancer Institute",
issn = "0027-8874",
publisher = "Oxford University Press",
number = "24",

}

TY - JOUR

T1 - Human IgM monoclonal antibody 16.88

T2 - Pharmacokinetics and immunogenicity in colorectal cancer patients

AU - Haisma, Hidde J.

AU - Pinedo, Herbert M.

AU - Kessel, Mieke A P

AU - Van Muijen, Monique

AU - Roos, Jan C.

AU - Plaizier, Marian A B D

AU - Martens, Harrie J M

AU - DeJager, Robert

AU - Boven, Epie

PY - 1991/12/18

Y1 - 1991/12/18

N2 - Twenty colorectal cancer patients were given an intravenous injection of human IgM monoclonal antibody (MAb) 16.88 (8 mg) conjugated to 131I for tumor localization. After a 2-week interval, a second injection with 200, 500, or 1000 mg of unlabeled antibody added was given to groups of five patients each. At the end of the 2-hour infusion, 66% of the radioactivity remained in the circulation. Blood clearance of the 131I-labeled MAb 16.88 was biphasic with a mean half-life (T1/2α) of 12 hours and T1/2β of 45 hours. Clearance rate was 0.09 L/hour. More than 90% of the 131I in serum was protein bound, with an immunoreactive fraction of 80% in the first 48 hours. Size exclusion chromatography indicated no degradation products other than 131I in serum and urine. The urinary excretion rate of 131I increased to 1.5% of the dose per hour at 24 hours, with 50% of the dose excreted in 34 hours. The pharmacokinetic profile of 131I-labeled MAb 16.88 was neither influenced by the total protein dose of antibody administered nor affected by specific uptake in tumor tissue in individual patients, as determined on early immunoscintigrams. The larger antibody doses showed a slightly slower excretion of 131I. The assays applied to determine immunogenicity were enzyme-linked immunosorbent assay, radioimmunoassay, and the dot-blot assay. They had sensitivities ranging from 5 ng/mL to 0.5 μg/mL for goat or rabbit antihuman IgM. The assays did not reveal antihuman antibody responses.

AB - Twenty colorectal cancer patients were given an intravenous injection of human IgM monoclonal antibody (MAb) 16.88 (8 mg) conjugated to 131I for tumor localization. After a 2-week interval, a second injection with 200, 500, or 1000 mg of unlabeled antibody added was given to groups of five patients each. At the end of the 2-hour infusion, 66% of the radioactivity remained in the circulation. Blood clearance of the 131I-labeled MAb 16.88 was biphasic with a mean half-life (T1/2α) of 12 hours and T1/2β of 45 hours. Clearance rate was 0.09 L/hour. More than 90% of the 131I in serum was protein bound, with an immunoreactive fraction of 80% in the first 48 hours. Size exclusion chromatography indicated no degradation products other than 131I in serum and urine. The urinary excretion rate of 131I increased to 1.5% of the dose per hour at 24 hours, with 50% of the dose excreted in 34 hours. The pharmacokinetic profile of 131I-labeled MAb 16.88 was neither influenced by the total protein dose of antibody administered nor affected by specific uptake in tumor tissue in individual patients, as determined on early immunoscintigrams. The larger antibody doses showed a slightly slower excretion of 131I. The assays applied to determine immunogenicity were enzyme-linked immunosorbent assay, radioimmunoassay, and the dot-blot assay. They had sensitivities ranging from 5 ng/mL to 0.5 μg/mL for goat or rabbit antihuman IgM. The assays did not reveal antihuman antibody responses.

UR - http://www.scopus.com/inward/record.url?scp=0026327427&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026327427&partnerID=8YFLogxK

M3 - Article

C2 - 1744925

AN - SCOPUS:0026327427

VL - 83

SP - 1813

EP - 1819

JO - Journal of the National Cancer Institute

JF - Journal of the National Cancer Institute

SN - 0027-8874

IS - 24

ER -